Neurochemical and psychotropic effects of bupropion in healthy male subjects

Journal of Clinical Psychopharmacology

Volumn 23, Issue 3, 2003, Pages 233-239

  Gobbi, Gabriella ^a   Slater, Susan ^a   Boucher, Nathalie ^a   Debonnel, Guy ^a   Blier, Pierre ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN; TYRAMINE;

ADULT; ARTICLE; ATTENTION; BEHAVIOR; BLOOD PRESSURE; BRAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ENERGY; HUMAN; MALE; NEUROCHEMISTRY; NORADRENALIN UPTAKE; NORADRENERGIC NERVE; PRESSOR RESPONSE; PRIORITY JOURNAL; PROFILE OF MOOD STATES SCALE; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; SCORING SYSTEM; SEROTONIN BLOOD LEVEL; SEROTONIN UPTAKE; SEROTONINERGIC NERVE CELL;

ADULT; AFFECT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; BUPROPION; CARRIER PROTEINS; DOUBLE-BLIND METHOD; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PSYCHOTROPIC DRUGS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS;

EID: 0038384130     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200306000-00004     Document Type: Article

References (48)

1. Ferris RM, White HL, Cooper BR, et al. Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin®). Drug Dev Res. 1981;1:21-35.
2. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J Clin Psychiatry. 1983;44:74-78.
3. Hyttel J. Citalopram-pharmacological profile of a specific serotonin reuptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Bíol Psychiatry. 1982;6:277-295.
4. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressant selectively block norepinephrine uptake. E J Pharmacol. 1984;104:277-286.
5. Perumal AS, Smith TM, Suckow RF, et al. Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine. Neuropharmacology. 1986;25:199-202.
6. Cooper BR, Wang CM, Cox RF, et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology. 1994;11:133-141.
7. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology. 2001;155:52-57.
8. Mongeau R, Weiss M, de Montigny C, et al. Effect of acute, shortand long-term milnacipran administration on rat locus caeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology. 1998;37:905-918.
9. Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci. 2001;13:2077-2087.
10. Posner J, Bye A, Dean K, et al. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol. 1985;29:97-103.
11. Goodnick PJ, Dominguez RA, DeVane CL, et al. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol Psych. 1988;44:629-632.
12. Reimherr FW, Cunningham LA, Batey SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained release bupropion tablets versus placebo in depressed outpatients. Clin Ther. 1998;20:505-516.
13. Arora RC, Meltzer HY. Imipramine binding in subpopulations of normal human blood platelets. Biol Psychiatry. 1984;19:257-262.
14. Pletscher A. Blood platelets as neuronal models: use and limitations. Clin Neuropharmacol. 1986;9(Suppl 4):344-346.
15. Demet EM, Halaris AE, Bhatarakamol S. Indoleamine compartmentation in human blood. Clin Chim Acta. 1978;16:285-292.
16. Artigas F, Sarrias MJ, Martinez E, et al. Serotonin in body fluids: characterization of human plasmatic and cerebrospinal fluid pools by means of a new HPLC method. Life Sci. 1985;5:37:441-447.
17. Zucker MB. Serotonin (5-hydroxytryptamine): haematological aspects. In: Toscantinis, ed. Progress in Haematology. New York: Grune and Stratton; 1965.
18. Ishigooka J, Nagata E, Takahashi A, et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentration following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Curr Ther Res. 1997;10:672, 679.
19. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Goodman Gilman A, Rall TW, et al., eds. The Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1990:187-220.
20. Ghose K, Gifford LA, Turner P, et al. Studies of the interaction of desmethylimipramine with tyramine in man after a single oral dose, and its correlation with plasma concentration. Br J Clin Pharmacol. 1976;3:334-337.
21. Ghose K, Turner P. Intravenous tyramine pressor response in depression. Lancet. 1975;1:1317-1318.
22. 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacol. 1983;22:1257-1267.
23. Lorr M, McNair DM, Fisher SU. Evidence for bipolar mood states. J Pers Assess. 1982;46:432-436.
24. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service, 1988.
25. Young SN, Smith SE, Pihl RO, et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 1985;87:173-177.
26. Leyton M, Young SN, Pihl RO, et al. Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology. 2000;22:52-63.
27. Fowle AS, Peck AW, Rogers HJ, et al. Failure of bupropion to affect the response to tyramine in man. Br J Clin Pharmacol. 1981;12:86-88.
28. Seppala T, Linnoila M, Soundergaard I, et al. Tyramine pressor test and cardiovascular effects of chlorimipramine and nortriptyline in healthy volunteers. Biol Psychiatry. 1981;16:71-77.
29. Debonnel G, Blier P, St-Andre E, et al. Comparison of the effect of low and high doses of venlafaxine on serotonin and norepinephrine reuptake processes in patients with major depression and healthy volunteers. Int J Neuropsychopharmacol. 1998;1(suppl 1):17.
30. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511-521.
31. Slater S, Gobbi G, Boucher N, et al. Effect of reboxetine on the norepinephrine reuptake process in healthy male subjects. N Clin Drug Eval Unit 2000;40:208.
32. Golden RN, Markey SP, Risby ED, et al. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988;45:150-154.
33. Garratt JC, Crespi F, Mason R, et al. Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur J Pharmacol. 1991;193:87-93.
34. 1A receptors. Eur J Pharmacol. 1994;260:79-83.
35. Haddjeri N, Blier P, de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther. 1996;277:861-871.
36. Little JT, Ketter TA, Mathé AA, et al. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biol Psychiatry. 1999;45:385-389.
37. Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 2002;on line:July 13.
38. Nomikos GG, Damsma G, Wenkstern D, et al. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology. 1992;7:7-14.
39. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology. 2002;42:181-190.
40. Golden RN, Rudorfer MV, Sherer MA, et al. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry. 1988;45:139-143.
41. Hamilton MJ, Smith PR, Peck AW. Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electro-encephalogram in health volunteers. Br J Clin Pharmacol. 1983;15:267-274.
42. Peck AW, Bye CE, Clubley M, et al. a comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol. 1979;7:469-478.
43. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288.
44. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40:307-314.
45. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry. 1993;11:2-14.
46. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321-327.
47. Tyler TD, Tessel RE. Norepinephrine uptake inhibitors as biochemically and behaviorally selective antagonists of the locomotor stimulation induced by indirectly acting sympathomimetic amines in mice. Psychopharmacology. 1980;69:27-34.
48. Lacroix D, Ferron A. Electrophysiological effects of methylphenidate on the coeruleo-cortical noradrenergic system in the rat. Eur J Pharmacol. 1988;149:277-285.